Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Xylos
AddedFeb 16, 2024
UpdatedJun 18, 2026
Xylos

Xylos

Public

Xylos Corp: A biomaterials-based medical device company offering surgical solutions and implants.

HQ
Langhorne, PA, US
Founded
1992
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize medical treatments through advanced biomaterials, Xylos Corporation focuses on developing innovative solutions for the treatment, repair, and replacement of human tissue. The company offers a range of surgical solutions and implants designed to improve patient outcomes and enhance the quality of life. Xylos aims to address critical needs in the healthcare market by providing cutting-edge, biocompatible products that integrate seamlessly with human tissue.

Xylos has garnered attention from notable investors and industry experts who recognize the potential of its pioneering technology. The company has achieved significant milestones in clinical trials and regulatory approvals, positioning itself as a leader in the biomaterials sector. Through its impactful innovations, Xylos is making substantial contributions to the medical field, offering new hope and improved treatment options for patients worldwide.

Xylos - Similar Companies

XyloCor Therapeutics logo

XyloCor Therapeutics

xylocor.com

Solx logo

Solx

Baxano Surgical logo

Baxano Surgical

baxanosurgical.com

Xtant Medical Holdings logo

Xtant Medical Holdings

xtantmedical.com

Novum Medical logo

Novum Medical

Cytophil logo

Cytophil

cytophil.com

Biophyx logo

Biophyx

biophyx.co

Xylyx Bio logo

Xylyx Bio

xylyxbio.com

XRad Therapeutics logo

XRad Therapeutics

XableCath logo

XableCath

Xeno Biosciences logo

Xeno Biosciences

Excelent logo

Excelent

TissueForm logo

TissueForm

tissueforminc.com

RevOrtho logo

RevOrtho

revortho.com

Biomimedica logo

Biomimedica

biomimedica.com

Xylos - Quick Facts

Who are Xylos' competitors?

Companies similar to Xylos include XyloCor Therapeutics, Solx, Baxano Surgical and Xtant Medical Holdings.

When was Xylos founded?

Xylos was founded in 1992.

Where is Xylos' headquarters located?

Xylos' headquarters is located in Langhorne, PA, US.

When was Xylos' last funding round?

Xylos' most recent funding round was for $1.5M (USD) in May 2010.

How much has Xylos raised to-date?

As of May 20, 2010, Xylos has raised a total of $1.5M (USD).

How many employees does Xylos have?

Xylos has 30 employees as of Feb 5, 2024.

Xylos - Classification

Industry
  • Hardware
Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Transactional
Customer
  • Consumers
  • Enterprise
Main Product
  • Implants
  • Surgical Solutions
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 9 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 330000Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies